FTSE 100 news / Companies and sectors / AstraZeneca / AstraZeneca efzimfotase alfa HICKORY phase III trial results
AstraZeneca efzimfotase alfa HICKORY phase III trial results
−1.7 slightly negative
Reports give mixed readings of the HICKORY trial, with differing accounts of whether endpoints were met.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| TradingView | 1 | +1.7 |
| AstraZeneca US | 1 | +0.8 |
| Securities.io | 1 | −7.5 |
Day by day
Monday 12 October 2026
Reports give mixed readings of the HICKORY trial, with differing accounts of whether endpoints were met.
- −7.5 AstraZeneca Efzimfotase Alfa Misses Primary Endpoint in HPP Trial
Efzimfotase alfa missed primary endpoint in HPP trial. - +1.7 Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49
Company framing mixed results, some improvement at weeks 25 and 49. - +0.8 Efzimfotase alfa showed numerical improvement in Six-Minute Walk Test achieving mean difference of 17.05 meters vs placebo in treatment-naïve adolescents and adults with hypophosphatasia at week 25 in HICKORY Phase III trial
Numerical improvement reported, but not clearly decisive.